News
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is one of the Best Extremely Profitable Stocks to Buy Right Now . On July 22, ...
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shares of Regeneron Pharmaceuticals Inc. REGN slid 1.35% to $564.64 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.07% to ...
Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” second-quarter 2025 investor letter ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 13th annual Regeneron Prize for Creative Innovation (the “Regeneron Prize”), which recognizes and rewards outstanding ...
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who ...
This was the stock's third consecutive day of gains.
Following an unprecedented AI chip demand, NVIDIA recently became the first company to reach a market capitalization of $4 ...
Following a recommendation from a panel of CDC advisors, HHS Secretary Robert F. Kennedy Jr. on Wednesday ordered that the preservative thimerosal be removed from all flu vaccines. In June, the CDC's ...
ANI Pharmaceuticals (ANIP) stock drops as its Iluvien implant fails in a clinical trial versus Eylea marketed by Regeneron ...
The atopic dermatitis market, valued at USD 9.33 billion in 2024, is projected to grow at a CAGR of 15.10%, reaching USD 38.07 billion by 2034. Key d ...
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results